Stocks of Exelixis Inc (EXEL) are poised to climb above their peers

With 3.08 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $20.67 whereas the lowest price it dropped to was $20.11. The 52-week range on EXEL shows that it touched its highest point at $24.34 and its lowest point at $16.15 during that stretch. It currently has a 1-year price target of $26.68. Beta for the stock currently stands at 0.53.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EXEL was down-trending over the past week, with a drop of -7.26%, but this was down by -13.32% over a month. Three-month performance dropped to -4.45% while six-month performance fell -2.18%. The stock gained 16.66% in the past year, while it has lost -15.92% so far this year. A look at the trailing 12-month EPS for EXEL yields 0.65 with Next year EPS estimates of 1.52. For the next quarter, that number is 0.23. This implies an EPS growth rate of 86.61% for this year and 24.92% for next year. EPS is expected to grow by 19.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -21.77%.


Float and Shares Shorts:

At present, 302.79 million EXEL shares are outstanding with a float of 301.17 million shares on hand for trading. On Jan 11, 2024, short shares totaled 8.56 million, which was 2.75% higher than short shares on Dec 14, 2023. In addition to Dr. Stelios Papadopoulos Ph.D. as the firm’s Co-Founder & Independent Chair of the Board, Dr. Michael M. Morrissey Ph.D. serves as its CEO, President & Director.

Institutional Ownership:

Through their ownership of 89.71% of EXEL’s outstanding shares, institutional investors have majority control over the company.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EXEL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With EXEL analysts setting a high price target of $32.00 and a low target of $18.00, the average target price over the next 12 months is $26.74. Based on these targets, EXEL could surge 58.65% to reach the target high and fall by -10.76% to reach the target low. Reaching the average price target will result in a growth of 32.57% from current levels.

Summary of Insider Activity:

Insiders traded EXEL stock several times over the past three months with 0 Buys and 1 Sells. In these transactions, 0 shares were bought while 19,020 shares were sold. The number of buy transactions has increased to 31 while that of sell transactions has risen to 42 over the past year. The total number of shares bought during that period was 2,421,590 while 1,307,498 shares were sold.